Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2007
11/15/2007WO2007128465A1 Xanthone derivative for the treatment of muscular disorders
11/15/2007WO2007128462A1 Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms
11/15/2007WO2007128459A1 Bicyclic tetrahydropyrrole compounds
11/15/2007WO2007128458A1 Bicyclic tetrahydropyrrole compounds
11/15/2007WO2007128454A1 3-tetrazolyl indazoles, 3-tetrazolyl pyrazolopyridines, and use thereof
11/15/2007WO2007128442A1 Use of an antipsychotic drug for the treatment of als-associated cachexia
11/15/2007WO2007128413A1 Pharmaceutical combination comprising 3- ( 3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and paracetamol
11/15/2007WO2007128412A1 Pharmaceutical combination comprising 3- (3-dimethylamin0-1-ethyl-2-methyl-pr0pyl) -phenol and an nsaid
11/15/2007WO2007128344A1 Design and synthesis of biotinylated probes for n-acyl-ethanolamines
11/15/2007WO2007128158A1 Transition metal complexes for inhibiting resistance in the treatment of cancer and metastasis
11/15/2007WO2007128109A1 Aptamers that recognize the carbohydrate n-acetylgalactosamine (galnac)
11/15/2007WO2007128107A1 Modified release tablets comprising tramadol
11/15/2007WO2007128088A2 Use of n-aminoimidazole cytoprotective compounds for treating cell death and/or gsk-3 mediated diseases
11/15/2007WO2007128059A1 Bis-pyridinium compounds
11/15/2007WO2007128056A1 Methods and composition for treatment of inflammatory pain
11/15/2007WO2007112968A3 Anti-inflammatory polymer
11/15/2007WO2007112173A8 Method for promoting composite tissue regeneration and uses thereof
11/15/2007WO2007111982A3 Methods for treating cognitive and other disorders
11/15/2007WO2007111925A3 Zotarolimus-containing drug delivery systems for implantation into a body lumen of a subject
11/15/2007WO2007109578A3 Substituted gamma lactams as prostaglandin ep2 agonists
11/15/2007WO2007109355A3 6,7,8, 9 -tetrahydro- 5h- pyrimido [4, 5-d] azepin-4-yl] -amine derivatives as modulators of trpvl for the treatment of pain
11/15/2007WO2007109160A9 Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
11/15/2007WO2007109088A3 Combinationtherapies of thiazolidinedione analogues and glucocorticoid agonists
11/15/2007WO2007109080A3 Deuterated hepatitis c protease inhibitors
11/15/2007WO2007109024A3 Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
11/15/2007WO2007108744A3 Novel quinazolines as 5-ht6 modulators
11/15/2007WO2007108743A3 Novel quinazolines as 5-ht6 modulators ii
11/15/2007WO2007108689A3 Method for induction of differentiation of stem and progenitor cells
11/15/2007WO2007107679A3 Association of oleaginous substance with a mixture of at least two cyclodextrins
11/15/2007WO2007107384A3 Soluble adenylate cyclase inhibitors
11/15/2007WO2007106554A3 Treatment and prevention of vascular hyperplasia using polyamine and polyamine analog compounds
11/15/2007WO2007106549A3 Method for treating brain cancer
11/15/2007WO2007105210A3 Therapeutic uses of cannabidiol compounds
11/15/2007WO2007104867A3 Cosmetic, pharmaceutical, food and veterinary compositions whose activating action on genes of sirtuin type makes it possible to delay ageing in mammals and the harmful effects thereof
11/15/2007WO2007100984A3 Beads containing pyridin-sulfinyl benzoimidazole sulfonyl phenoxy acetate derivatives
11/15/2007WO2007099323A3 Quinoline derivatives
11/15/2007WO2007099171A3 Bicyclo-pyrazoles active as kinase inhibitors
11/15/2007WO2007098390A3 Method for treating resistant hypertension
11/15/2007WO2007096753A3 Process for preparing highly pure simvastatin
11/15/2007WO2007095050A3 N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
11/15/2007WO2007093624A3 Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin
11/15/2007WO2007093617A3 New stable hyperbaric composition comprising prilocaine hcl, use of said new composition for intrathecal anaesthesia, and method for manufacturing said composition
11/15/2007WO2007090579A3 Substituted quinolones iii
11/15/2007WO2007090141A3 Pyrrolo [2, 3, b] pyridine derivatives useful as raf kinase inhibitors
11/15/2007WO2007089906A3 Cationic steroid antimicrobial compositions for treating or preventing herpes infections
11/15/2007WO2007089703A3 Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
11/15/2007WO2007089678A3 Potassium channel inhibitors
11/15/2007WO2007089291A3 Estrogen receptor modulators
11/15/2007WO2007087504A3 Compounds for the treatment of metabolic disorders
11/15/2007WO2007087224A3 Hexahydro-3h-pyrrolizin-3-ones useful as tachykinin receptor antagonists
11/15/2007WO2007087151A3 Combination of ache inhibitor and 5-ht6 antagonist for the treatment of cognitive dysfunction
11/15/2007WO2007086536A3 Soft-gelatin capsule formulation
11/15/2007WO2007084591A3 Novel solid forms of (4r)-1-[4-(2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl]-1,2,3,5-tetrahydro-spiro[4h-1-benzazepine-4,1'-[2]cyclopentene]-3'-carboxylic acid
11/15/2007WO2007084560A8 INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH
11/15/2007WO2007084332A3 Memantine for the normalization of visual acuity deficits
11/15/2007WO2007083182A3 Novel heterocycles
11/15/2007WO2007079390A3 Medicament for topical use
11/15/2007WO2007079173A3 Novel 2-heteroaryloxy-phenol derivatives as antibacterial agents
11/15/2007WO2007078523A3 5-phenyl-3-benzyl-0xaz0lidin-2-0ne derivatives and related compounds as metabotropic glutamate receptor potentiators for the treatment of neurological and psychiatric disorders
11/15/2007WO2007077186A8 Pdf inhibitors
11/15/2007WO2007076875A3 Compounds acting on the serotonin transporter
11/15/2007WO2007076379A3 4,7-dihydrothieno[2,3-b]pyridine compounds and pharmaceutical compositions
11/15/2007WO2007076160A3 C-10 carbamates of taxanes
11/15/2007WO2007076131A3 Compositions comprising polycation-complexed protein crystals and methods of treatment using them
11/15/2007WO2007076092A3 Nitrogen- containing bicyclic hetroaryl compounds for the treatment of raf protein kinase-mediated diseases
11/15/2007WO2007075923A3 Treatment of synucleinopathies
11/15/2007WO2007075695A3 Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
11/15/2007WO2007075650A3 Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders
11/15/2007WO2007075525A3 Combination of an iap-inhibitor and a taxane7
11/15/2007WO2007074169A3 Compositions and methods for the inhibition of phospholipase a2
11/15/2007WO2007070600A3 N-(5-membered heteroaromatic ring)-amido anti-viral compounds
11/15/2007WO2007070504A3 Stable and palatable oral liquid sumatriptan compositions
11/15/2007WO2007067836A3 Substituted pyrazole compounds useful as soluble epoxide hydrolase inhibitors
11/15/2007WO2007067615A3 Thiadiazole derivatives as antidiabetic agents
11/15/2007WO2007067416A3 Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
11/15/2007WO2007066337A3 Jasmonate derivatives, pharmaceutical compositions and methods of use thereof
11/15/2007WO2007065093A3 Pyrrolidineanilines
11/15/2007WO2007064881A3 Implantable microbial cellulose materials for various medical applications
11/15/2007WO2007062339A3 Liquid formulations
11/15/2007WO2007062167A3 Method of modulating stress-activated protein kinase system
11/15/2007WO2007061764A3 Tricyclic compounds useful as inhibitors of kinases
11/15/2007WO2007061696A3 Spirolactam bicyclic cgrp receptor antagonists
11/15/2007WO2007061458A3 S1p receptor modulating compounds and use thereof
11/15/2007WO2007059874A3 Compositions for the treatment of osteoarthritis and to nourish the synovial fluid
11/15/2007WO2007058942A3 Imidazopyrazines as protein kinase inhibitors
11/15/2007WO2007056683A3 Novel chemical compounds
11/15/2007WO2007056469A3 Certain chemical entities, compositions, and methods
11/15/2007WO2007056112A3 Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
11/15/2007WO2007050401A3 Tyrosine kinase inhibitors
11/15/2007WO2007047607A3 Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
11/15/2007WO2007043057A3 Compositions for nasal delivery
11/15/2007WO2007033099A3 Prodrugs of phentermine
11/15/2007WO2007030455A3 Mutations and polymorphisms of hdac10
11/15/2007WO2007024752A3 Methods and compositions for the treatment and diagnosis of endothelial cell disorders and angiogenic disorders
11/15/2007WO2007022073A3 Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives
11/15/2007WO2007019065A3 Adjuvant chemotherapy for anaplastic gliomas
11/15/2007WO2007016155A3 Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
11/15/2007WO2007014285A3 Compositions of polyacids and polyethers and methods for their use as dermal fillers
11/15/2007WO2007014054A3 Benzenesulfonamide inhibitor of ccr2 chemokine receptor
11/15/2007WO2007002481A3 Non-nucleoside reverse transcriptase inhibitors
1 ... 3499 3500 3501 3502 3503 3504 3505 3506 3507 3508 3509 3510 3511 3512 3513 3514 3515 3516 3517 3518 3519 ... 7860